Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Sorafenib 42Bevacizumab 16Oxaliplatin 13Radiosurgery 10Gemcitabine 10Doxorubicin 10Capecitabine 10Leucovorin 9Hepatectomy 9Fluorouracil 9Cisplatin 9Radiofrequency Ablation 8Nivolumab 8pembrolizumab 7Drug Therapy 7Carboplatin 7Irinotecan 6Cryosurgery 6Talaporfin 5Mitomycin 5Everolimus 5Erlotinib Hydrochloride 5Electroporation 5spartalizumab 4Sunitinib 4Melphalan 4Ipilimumab 4Epirubicin 4Embolization, Therapeutic 4regorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Liver Neoplasms × NIS-793 × Clear all
NCT02947165 2022-01-31

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

Novartis

Phase 1 Completed
120 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡